Cargando…

Experience of a Single Center in NTBC Use in Management of Hereditary Tyrosinemia Type I in Libya

BACKGROUND: Hereditary Tyrosinemia type I (HTI) is a metabolic disease caused by deficiency of fumarylacetoacetate hydrolase enzyme. OBJECTIVES: This study reports beside its clinical and biochemical presentation, the outcome of NTBC [2- (2-nitro-4-trifloro-methylbenzoyl)-1, 3-cyclohexanedion] treat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alobaidy, Hanna, Barkaoui, Emna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Kowsar 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4610339/ https://www.ncbi.nlm.nih.gov/pubmed/26495099 http://dx.doi.org/10.5812/ijp.3608

Ejemplares similares

Neurological Crises after Discontinuation of Nitisinone (NTBC) Treatment in Tyrosinemia
por: HONAR, Naser, et al.
Publicado: (2017)

Blood and Brain Biochemistry and Behaviour in NTBC and Dietary Treated Tyrosinemia Type 1 Mice
por: van Ginkel, Willem G., et al.
Publicado: (2019)

Emotional and behavioral problems, quality of life and metabolic control in NTBC-treated Tyrosinemia type 1 patients
por: van Vliet, Kimber, et al.
Publicado: (2019)

NTBC Treatment Monitoring in Chilean Patients with Tyrosinemia Type 1 and Its Association with Biochemical Parameters and Liver Biomarkers
por: Fuenzalida, Karen, et al.
Publicado: (2021)

Daily variation of NTBC and its relation to succinylacetone in tyrosinemia type 1 patients comparing a single dose to two doses a day
por: Kienstra, Nienke S., et al.
Publicado: (2017)

Patterns of inborn errors of metabolism: A 12 year single-center hospital-based study in Libya
por: AlObaidy, Hanna
Publicado: (2013)

Therapeutic Targeting of Fumaryl Acetoacetate Hydrolase in Hereditary Tyrosinemia Type I
por: Gil-Martínez, Jon, et al.
Publicado: (2021)

Syndrome of hereditary tyrosinemia in mink
por: Christensen, K, et al.
Publicado: (1978)

Revisiting hereditary tyrosinemia Type 1—spectrum of radiological findings
por: Shaikh, Sana, et al.
Publicado: (2018)

Hereditary Tyrosinemia Type 1 in Jordan: A Retrospective Study
por: Megdadi, Noor A., et al.
Publicado: (2021)

Heat Shock Response Associated with Hepatocarcinogenesis in a Murine Model of Hereditary Tyrosinemia Type I
por: Angileri, Francesca, et al.
Publicado: (2014)

Clinical experience with hepatorenal tyrosinemia from a single Egyptian center
por: El-Karaksy, Hanaa, et al.
Publicado: (2022)

Hereditary tyrosinemia. Formation of succinylacetone-amino acid adducts
Publicado: (1985)

Protein Degradation and the Pathologic Basis of Phenylketonuria and Hereditary Tyrosinemia
por: Sarodaya, Neha, et al.
Publicado: (2020)

Clinical utility of nitisinone for the treatment of hereditary tyrosinemia type-1 (HT-1)
por: Das, Anibh Martin
Publicado: (2017)

Fumarylacetoacetate Hydrolase Knock-out Rabbit Model for Hereditary Tyrosinemia Type 1
por: Li, Li, et al.
Publicado: (2017)

Phenotype, genotype, and outcome of 25 Palestinian patients with hereditary tyrosinemia type 1
por: Dweikat, Imad, et al.
Publicado: (2021)

Efficient liver repopulation of transplanted hepatocyte prevents cirrhosis in a rat model of hereditary tyrosinemia type I
por: Zhang, Ludi, et al.
Publicado: (2016)

Generation of immunodeficient pig with hereditary tyrosinemia type 1 and their preliminary application for humanized liver
por: Ren, Jilong, et al.
Publicado: (2022)

Hereditary tyrosinemia type I–associated mutations in fumarylacetoacetate hydrolase reduce the enzyme stability and increase its aggregation rate
por: Macias, Iratxe, et al.
Publicado: (2019)

Casein Glycomacropeptide: An Alternative Protein Substitute in Tyrosinemia Type I
por: Daly, Anne, et al.
Publicado: (2021)

Hereditary Tyrosinemia Compounded With Hyperinsulinemic Hypoglycemia: Challenging Diagnosis of a Rare Case
por: Nasir, Sharmeen, et al.
Publicado: (2020)

Hepatorenal tyrosinemia
por: KITAGAWA, Teruo
Publicado: (2012)

Diagnostic and Therapeutic Challenges of Hereditary Tyrosinemia Type 1 in Lebanon: A 12-Year Retrospective Review
por: Daou, Karim N., et al.
Publicado: (2021)

Initial presentation, management and follow-up data of 33 treated patients with hereditary tyrosinemia type 1 in the absence of newborn screening
por: Hajji, Hela, et al.
Publicado: (2022)

Tyrosinemia type III in an asymptomatic girl
por: Szymanska, Edyta, et al.
Publicado: (2015)

Comment on Pancreatitis in Type 1 Tyrosinemia
por: Rahmoune, Hakim, et al.
Publicado: (2017)

Case of hepatocellular carcinoma in a patient with hereditary tyrosinemia in the post-newborn screening era
por: Imseis, Essam M, et al.
Publicado: (2017)

Treatment adherence in tyrosinemia type 1 patients
por: González-Lamuño, Domingo, et al.
Publicado: (2021)

Identification of circulating microRNAs during the liver neoplastic process in a murine model of hereditary tyrosinemia type 1
por: Angileri, Francesca, et al.
Publicado: (2016)

The future of gene-targeted therapy for hereditary tyrosinemia type 1 as a lead indication among the inborn errors of metabolism
por: Thompson, Whitney S., et al.
Publicado: (2020)

In vivo lentiviral vector gene therapy to cure hereditary tyrosinemia type 1 and prevent development of precancerous and cancerous lesions
por: Nicolas, Clara T., et al.
Publicado: (2022)

Hereditary Tyrosinemia Type 1 Mice under Continuous Nitisinone Treatment Display Remnants of an Uncorrected Liver Disease Phenotype
por: Neuckermans, Jessie, et al.
Publicado: (2023)

Open-Label Single-Sequence Crossover Study Evaluating Pharmacokinetics, Efficacy, and Safety of Once-Daily Dosing of Nitisinone in Patients with Hereditary Tyrosinemia Type 1
por: Guffon, Nathalie, et al.
Publicado: (2017)

Long-Term Outcomes and Practical Considerations in the Pharmacological Management of Tyrosinemia Type 1
por: van Ginkel, Willem G., et al.
Publicado: (2019)

A Rapid Screening Test on Dried Blood for the Neonatal Diagnosis of Tyrosinemia Type I
por: Bodaghkhan, Farahnaz, et al.
Publicado: (2016)

Tyrosine catabolites influence SKN-1 signaling in a model of Type I Tyrosinemia
por: Siddiqi, Talha F, et al.
Publicado: (2022)

Type 1 tyrosinemia in Finland: a nationwide study
por: Äärelä, Linnea, et al.
Publicado: (2020)

Case report: ADHD and prognosis in tyrosinemia type 1
por: Barone, Helene, et al.
Publicado: (2023)

Exploring the therapeutic potential of modern and ancestral phenylalanine/tyrosine ammonia-lyases as supplementary treatment of hereditary tyrosinemia
por: Hendrikse, Natalie M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_r6gdnsfq0cbn1e0dbln5f2sinv